Phase II Trial of Bolus Interleukin-2 in Previously Treated Lung Cancer
OBJECTIVES: I. Determine the response rate and median duration of response of interleukin-2
(IL-2) in patients with previously treated non-small cell lung cancer. II. Determine the
median survival of patients treated with IL-2. III. Further delineate the toxicity of IL-2
in these patients.
OUTLINE: This is an open label study. Patients receive bolus interleukin-2 on days 1-5 and
8-12. The cycle repeats every 3 weeks. Patient response is evaluated after 2 cycles.
Patients with stable disease, partial, or complete response may be treated with maintenance
IL-2 for up to 4 additional cycles. Patient evaluation is performed after every 2 cycles. At
this point, patients with stable or responding disease may be treated with IL-2 every 6
weeks until disease progression, intolerable toxic effects, or 2 cycles beyond complete
PROJECTED ACCRUAL: A maximum of 30 patients will be accrued.
Primary Purpose: Treatment
Datchen F. Tai, MD
Cancer Biotherapy Research Group
United States: Federal Government
|Bloomington, Indiana 47402
|Bergan Mercy Medical Center
|Omaha, Nebraska 68124
|St. Joseph Regional Cancer Center
|Bryan, Texas 77802